Nianhang Chen

TL;DR: Renal impairment did not alter the oral absorption, protein binding, or nonrenal elimination of lenalidomide, and a single 25‐mg dose was well tolerated by renally impaired subjects.

TL;DR: It is concluded that lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas and delays whole brain radiotherapy (WBRT) in patients with inadequate responses to lenalidumide.

TL;DR: At a given exposure level, neutropenia development was positively correlated with increasing age but not significantly influenced by hepatic function, tumor type, sex, or dosing schedule, which supports exposure‐matched dose adjustments in patients with moderate to severe hepatic impairment.

TL;DR: Sotatercept was generally safe and well tolerated, and elicited clinically significant, dose‐dependent increases in hemoglobin, hematocrit, and red blood cell counts that persisted for up to 4 months, as well as increased bone mineral density and biomarkers of bone formation.

TL;DR: Nab-paclitaxel demonstrated more efficient transport across endothelial cells, greater penetration and cytotoxic induction in xenograft tumors, and enhanced extravascular distribution in patients that are attributed to carrier-mediated transport.